135 research outputs found

    ”PENINGKATAN KUALITAS PELAYANAN JASA PADA DEPARTEMEN UMUM DAN LOGISTIK MELALUI PENDEKATAN INTEGRASI METODE SERVQUAL SIX SIGMA” (Study Kasus PT. Slena Cahaya Gemilang Surabaya)

    Get PDF
    Penelitian ini bertujuan untuk mengetahui dan menganalisa seberapa besar pengaruh kualitas pelayanan jasa terhadap tingkat kepuasan yang dirasakan oleh pelanggan yang menggunakan jasa EMKL PT. Selena Cahaya Gemilang. Model yang digunakan dalam penelitian ini adalah metode observasi, wawancara, kuesioner, dan studi kepustakaan dengan menggunakan skala likert dan metode penentuan sampel yang digunakan adalah aksidental sampling sebanyak 100 sampel. Metode analisis yang digunakan adalah metode regresi linear berganda (multi linear regression). Hasil penelitian menunjukkan bahwa kualitas pelayanan yang terdiri atas Realibility (X1), Responsiveness (X2), Assurance (X3), Emphaty (X4), dan Tangible (X5) secara bersama- sama memiliki pengaruh yang positif. Di mana persamaan regresi Y = 196.7 X1 + 213.2 X2 + 158.2 X3 + 183.8 X4 + 198 X5. Selain itu, dengan uji validasi dilihat bahwa kualitas pelayanan memiliki pengaruh yang signifikan terhadap kepuasan pelanggan dengan tingkat signifikansi sebesar 0,000 atau 0%.

    Prevalence, risk factors, and impact on outcome of cytomegalovirus replication in serum of Cambodian HIV-infected patients (2004-2007)

    Get PDF
    BACKGROUND: In developing countries, the study of cytomegalovirus (CMV) coinfection in HIV-infected patients remains neglected. Quantitative CMV polymerase chain reaction (PCR) is the gold standard diagnostic tool for analyzing serum CMV replication and for predicting CMV disease. We estimated the prevalence of replicating CMV in sera of newly diagnosed HIV-infected Cambodian patients and examined its impact on mortality. METHODS: This cohort study was based on 2 highly active antiretroviral therapy treatment programs in Cambodia between 2004 and 2007. Quantitative CMV PCR was performed on baseline serum samples of 377 HIV-infected patients. RESULTS: The prevalence of serum CMV DNA was 55.2% (150 of 272) in patients with CD4 count <100/mm. In multivariate analysis, hemoglobin <9 g/dL, CD4 count <100/mm, and Karnofsky index <50 were independently associated with positive serum CMV DNA at baseline. During a 3-year follow-up period, CMV viral load >or=3.1 log10 copies per milliliter was significantly associated with death independently of CD4 count, other opportunistic infections, and highly active antiretroviral therapy. CONCLUSIONS: As in industrialized countries, serum CMV replication is highly prevalent among HIV-infected Cambodian patients and is associated with increased mortality. This underscores the importance of diagnostic CMV infection by PCR in sera of HIV-infected patients with CD4 count <100/mm and treating this opportunistic infection to reduce its associated mortality

    AIDS and Cancer Specimen Resource (ACSR)

    Get PDF
    The AIDS and Cancer Specimen Resource (ACSR) has four regional biorepositories (RBRs) in the United States and one in South Africa. The ACSR is funded by the National Cancer Institute (NCI) of the National Institutes of Health (United States) to support investigators studying HIV/AIDS and HIV/AIDS-associated malignancies. The ACSR inventory includes more than 450,000 annotated HIV-positive biospecimens from over 10,000 individuals and 100,000 HIV-negative controls from approximately 4,250 individuals, reflecting the pre-highly active antiretroviral therapy (HAART) and post-HAART era of the HIV epidemic, as well as selected geographic regions heavily impacted by this global pandemic. Funding statement: The U.S. NIH National Cancer Institute has funded the ACSR since 1994. The present award is UM1CA181255

    Shipment Impairs Lymphocyte Proliferative Responses to Microbial Antigens

    Get PDF
    Lymphocyte proliferation assays (LPAs) are widely used to assess T-lymphocyte function of patients with human immunodeficiency virus infection and other primary and secondary immunodeficiency disorders. Since these assays require expertise not readily available at all clinical sites, specimens may be shipped to central labs for testing. We conducted a large multicenter study to evaluate the effects of shipping on assay performance and found significant loss of LPA activity. This may lead to erroneous results for individual subjects and introduce bias into multicenter trials

    CMV quantitative PCR in the diagnosis of CMV disease in patients with HIV-infection – a retrospective autopsy based study

    Get PDF
    Background Patients with advanced HIV infection at the time of diagnosis and patients not responding to antiretroviral therapy are at risk of cytomegalovirus (CMV) disease. Earlier studies of patients with HIV infection have demonstrated that the diagnosis is often first made post-mortem. In recent years new molecular biological tests have become available for diagnosis of CMV disease. Although clinical evaluation of tests for diagnosis of CMV disease in HIV-infected individuals is suboptimal without autopsy, no results from such studies have been published. The aim of this study was to explore the diagnostic utility of CMV quantitative polymerase chain reaction (PCR) in plasma from HIV and CMV seropositive patients who died during the period 1991–2002 and in whom autopsy was performed. Methods Autopsy was performed in all cases, as part of routine evaluation of HIV-infected cases followed at Ullevaal University Hospital. Of 125 patients included, 53 had CMV disease, 37 of whom were first diagnosed at autopsy. CMV disease was diagnosed either by ophthalmoscopic findings typical of CMV retinitis, biopsy or autopsy. One or two plasma samples taken prior to the first diagnosis of CMV disease (alive or at autopsy) or death without CMV disease were analysed by CMV quantitative PCR. Sensitivity, specificity, positive and negative predictive values were calculated for different CMV viral load cut-offs and according to detection of viraemia in one versus two samples. Results Twenty-seven of 53 patients with CMV disease (51%) and 10 of 72 patients without CMV disease (14%) had detectable viraemia in at least one sample. Sensitivity and negative predictive value (NPV) of the test, maximised with a cut-off at the test's limit of detection of CMV viraemia (400 copies/mL), were 47% and 70%, respectively. With cut-off at 10 000 copies/mL, specificity and positive predictive value (PPV) were 100%. With a requirement for CMV viraemia in two samples, specificity and PPV were 100% in patients with CMV viraemia above the limit of detection. Conclusion Our results indicate that quantitative CMV PCR is best used to rule in, rather than to rule out CMV disease in HIV-infected individuals at high risk

    Elite Suppressor–Derived HIV-1 Envelope Glycoproteins Exhibit Reduced Entry Efficiency and Kinetics

    Get PDF
    Elite suppressors (ES) are a rare subset of HIV-1–infected individuals who are able to maintain HIV-1 viral loads below the limit of detection by ultra-sensitive clinical assays in the absence of antiretroviral therapy. Mechanism(s) responsible for this elite control are poorly understood but likely involve both host and viral factors. This study assesses ES plasma-derived envelope glycoprotein (env) fitness as a function of entry efficiency as a possible contributor to viral suppression. Fitness of virus entry was first evaluated using a novel inducible cell line with controlled surface expression levels of CD4 (receptor) and CCR5 (co-receptor). In the context of physiologic CCR5 and CD4 surface densities, ES envs exhibited significantly decreased entry efficiency relative to chronically infected viremic progressors. ES envs also demonstrated slow entry kinetics indicating the presence of virus with reduced entry fitness. Overall, ES env clones were less efficient at mediating entry than chronic progressor envs. Interestingly, acute infection envs exhibited an intermediate phenotypic pattern not distinctly different from ES or chronic progressor envs. These results imply that lower env fitness may be established early and may directly contribute to viral suppression in ES individuals

    Clinical Predictors of Immune Reconstitution following Combination Antiretroviral Therapy in Patients from the Australian HIV Observational Database

    Get PDF
    A small but significant number of patients do not achieve CD4 T-cell counts >500 cells/Β΅l despite years of suppressive cART. These patients remain at risk of AIDS and non-AIDS defining illnesses. The aim of this study was to identify clinical factors associated with CD4 T-cell recovery following long-term cART.Patients with the following inclusion criteria were selected from the Australian HIV Observational Database (AHOD): cART as their first regimen initiated at CD4 T-cell count <500 cells/Β΅l, HIV RNA<500 copies/ml after 6 months of cART and sustained for at least 12 months. The Cox proportional hazards model was used to identify determinants associated with time to achieve CD4 T-cell counts >500 cells/Β΅l and >200 cells/Β΅l.501 patients were eligible for inclusion from AHOD (nβ€Š=β€Š2853). The median (IQR) age and baseline CD4 T-cell counts were 39 (32-47) years and 236 (130-350) cells/Β΅l, respectively. A major strength of this study is the long follow-up duration, median (IQR)β€Š=β€Š6.5(3-10) years. Most patients (80%) achieved CD4 T-cell counts >500 cells/Β΅l, but in 8%, this took >5 years. Among the patients who failed to reach a CD4 T-cell count >500 cells/Β΅l, 16% received cART for >10 years. In a multivariate analysis, faster time to achieve a CD4 T-cell count >500 cells/Β΅l was associated with higher baseline CD4 T-cell counts (p<0.001), younger age (pβ€Š=β€Š0.019) and treatment initiation with a protease inhibitor (PI)-based regimen (vs. non-nucleoside reverse transcriptase inhibitor, NNRTI; pβ€Š=β€Š0.043). Factors associated with achieving CD4 T-cell counts >200 cells/Β΅l included higher baseline CD4 T-cell count (p<0.001), not having a prior AIDS-defining illness (pβ€Š=β€Š0.018) and higher baseline HIV RNA (p<0.001).The time taken to achieve a CD4 T-cell count >500 cells/Β΅l despite long-term cART is prolonged in a subset of patients in AHOD. Starting cART early with a PI-based regimen (vs. NNRTI-based regimen) is associated with more rapid recovery of a CD4 T-cell count >500 cells/Β΅l

    HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy

    Get PDF
    BACKGROUND:The clinical significance and cellular sources of residual human immunodeficiency virus type 1 (HIV-1) production despite suppressive combination antiretroviral therapy (cART) remain unclear and the effect of low-level viremia on T-cell homeostasis is still debated. METHODOLOGY/PRINCIPAL FINDINGS:We characterized the recently produced residual viruses in the plasma and short-lived blood monocytes of 23 patients with various immunological responses to sustained suppressive cART. We quantified the residual HIV-1 in the plasma below 50 copies/ml, and in the CD14(high) CD16(-) and CD16+ monocyte subsets sorted by flow cytometry, and predicted coreceptor usage by genotyping V3 env sequences. We detected residual viremia in the plasma of 8 of 10 patients with poor CD4+ T-cell reconstitution in response to cART and in only 5 of 13 patients with good CD4+ T-cell reconstitution. CXCR4-using viruses were frequent among the recently produced viruses in the plasma and in the main CD14(high) CD16(-) monocyte subset. Finally, the residual viremia was correlated with persistent CD4+ and CD8+ T-cell activation in patients with poor immune reconstitution. CONCLUSIONS:Low-level viremia could result from the release of archived viruses from cellular reservoirs and/or from ongoing virus replication in some patients. The compartmentalization of the viruses between the plasma and the blood monocytes suggests at least two origins of residual virus production during effective cART. CXCR4-using viruses might be produced preferentially in patients on cART. Our results also suggest that low-level HIV-1 production in some patients may contribute to persistent immune dysfunction despite cART
    • …
    corecore